Gene Factors and Serotypes Related to Polysaccharide and Protein-Based Candidate Vaccines Among Streptococcus...

A new strategy to reduce the morbidity and mortality associated with invasive Streptococcus agalactiae (Streptococcus group B, GBS) diseases encompasses the development of vaccines. Candidate vaccines at different stages of clinical trials have been developed on capsular polysaccharides or protein antigens. We studied 328 GBS isolates identified using routine microbiological tests, latex-agglutination, and PCRs. The samples were categorised into two main groups: vaginal (69.2%) and extra-vaginal (30.8%). The molecular serotyping and target gene factors were determined using singleplex or multiplex PCRs. The most common serotypes identified were Ia (24.7%), V (22.0%), and III (18.9%). Serotypes I-V constituted a total of 89.0%. The non-typeable were 9.8%. The frequency of genes included in the recombinant GBS-NN (rib + bca) and GBS-NN2 (epsilon + alp2/3) vaccines were 54.3% and 40.8%. We noted a significant prevalence in the distribution of serotypes II, III, and non-typeable in GBS-NN, whereas serotypes Ia and IV were predominant in GBS-NN2. The serotype prevalence identified in our research was consistent with the data from our region and confirmed the predominance of the six main serotypes included in the hexavalent conjugated vaccine. We highlighted the importance of the combined administration of both protein vaccines, ensuring optimal vaccine coverage.